Jose Baselga, MD, PhD

Articles

Dr. Baselga on Biomarker Research for Breast Cancer

September 16th 2017

José Baselga, MD, PhD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses biomarker research for patients with breast cancer.

Dr. Baselga Discusses Fine Tuning Drug Doses

May 13th 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses the need to fine tune mTOR and PI3K inhibitor doses.

Dr. Baselga Discusses Upcoming BOLERO-3 Data

April 18th 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses everolimus and the upcoming data from the BOLERO-3 trial in breast cancer.

Dr. Baselga Discusses PIK3CA Inhibitors in Breast Cancer

March 29th 2013

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, discusses treatment with PIK3CA inhibitors in patients with breast cancer.

Dr. Baselga Compares mTOR Inhibitors in Breast Cancer

December 3rd 2012

José Baselga, MD, PhD, Physician-in-Chief, Memorial Sloan-Kettering Cancer Center, compares results from two trials analyzing the mTOR inhibitors temsirolimus and everolimus in breast cancer.

Dr. Baselga on pan-PI3K Inhibitors in Breast Cancer

November 20th 2012

José Baselga, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the investigation of pan-PI3K inhibitors for patients with metastatic breast cancer.

Dr. Baselga on Combining Pertuzumab with Trastuzumab

June 8th 2012

Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab

Dr. Baselga Discusses the BOLERO Breast Cancer Trials

March 5th 2012

Dr. Jose Baselga from Massachusetts General Hospital Discusses the BOLERO Breast Cancer Trials

Dr. Baselga on the Basis Behind the BOLERO-2 Trial

February 7th 2012

Dr. Jose Baselga, from Massachusetts General Hospital, Describes the Basis Behind the BOLERO-2 Trial

Dr. Baselga Describes the Advantages of Dual Blockade

December 14th 2011

Dr. Jose Baselga from Massachusetts General Hospital Describes the Advantages of Dual Blockade

x